Evidence-based treatment limitations prevent any therapeutic recommendation for acute poststreptococcal glomerulonephritis in children.
The majority of children with the epidemic form of acute post-streptococcal glomerulonephritis (APSGN) have an excellent prognosis, which contrasts with the poor long-term outcome of sporadic cases. Therapy is largely supportive. Rarely, the disease shows long-term complications, worsening to chronic kidney disease requiring long-term interventional measures. To compare the effectiveness of different therapeutic strategies for the prevention and treatment of APSGN in childhood, the authors reviewed randomized controlled trials on the prevention and treatment of APSGN in children. Nine studies fit the inclusion criteria. Primary outcomes were the development of APSGN, the effectiveness of medication for controlling hypertension, and the development of chronic renal failure in patients with crescentic glomerulonephritis. No advantages of antimicrobials (cefuroxim, ceftibuten, and others) given for 5 days were found over penicillin V given for 10 days (4 trials). Nifedipine showed advantages in controlled acute hypertension (1 trial). ACE inhibitors (captopril and enalapril) had better control of blood pressure and echocardiographic changes than other antihypertensive drugs/diuretics (2 trials). The use of combined immunosuppressants for crescentic poststreptococcal glomerulonephritis showed no advantages over supportive therapy alone (1 study). The studies were of small number and with limitations that seriously weaken the results.
Zaffanello
Marco
M
Department of Mother-Child and Biology-Genetics, University of Verona, 37134 Verona, Italy. marco.zaffanello@univr.it
Cataldi
Luigi
L
Franchini
Massimo
M
Fanos
Vassilios
V
D000293:Adolescent; D000890:Anti-Infective Agents / Q000494:pharmacology; D001794:Blood Pressure; D002648:Child; D002675:Child, Preschool; D004452:Echocardiography / Q000379:methods; D019317:Evidence-Based Medicine; D005921:Glomerulonephritis / Q000628:therapy*; D017408:Guidelines as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007223:Infant; D007231:Infant, Newborn; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D017063:Outcome Assessment, Health Care; D013290:Streptococcal Infections / Q000150:complications*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D007166:Immunosuppressive Agents